The warrant exchange is a clear positive — retiring 1M shares at no cost while issuing pre-funded warrants (which are unlikely to be exercised given the 9.99% ownership cap) reduces the overhang. Combined with a $137.9M cash runway into H2 2028 and advancing pipeline catalysts (KRRO-121 regulatory filing, KRRO-111 development candidate), this removes a key near-term dilution risk. Monitor for KRRO-121 regulatory approval in H2 2026 as the primary catalyst.
Price Chart
Executive Summary
Korro Bio reported Q2 2026 results with a net loss of $18.9M ($1.07/share) vs $25.8M ($2.74/share) in Q2 2025, with cash of $137.9M providing runway into H2 2028. The company also executed a warrant exchange with Venrock, surrendering 1M common shares for 1M pre-funded warrants (exercise price $0.001), reducing the share count to 13.7M shares outstanding. Pipeline progress includes EMA Orphan Drug Designation for KRRO-121 and nomination of KRRO-111 as an AATD development candidate, with KRRO-121 on track for regulatory filing in H2 2026. The combination of a reduced share count, strong cash position, and advancing pipeline catalysts is a net positive for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss of $18.9M for Q2 2026, improved from $25.8M in Q2 2025
- Cash, cash equivalents and marketable securities of $137.9M as of June 30, 2026
- Cash runway into second half of 2028
- Warrant exchange: Venrock surrendered 1M common shares for 1M pre-funded warrants (exercise price $0.001)
- Post-exchange shares outstanding: 13,725,646 common shares; 4,148,836 unexercised pre-funded warrants
- KRRO-121 received Orphan Drug Designation from EMA for UCDs
- KRRO-111 nominated as development candidate for AATD
- KRRO-121 on track for regulatory filing in H2 2026
- R&D expenses $13.6M in Q2 2026 vs $20.1M in Q2 2025
- No collaboration revenue in Q2 2026 due to Novo Nordisk collaboration pause
Financial Impact
Net loss improved by $6.9M YoY; cash burn rate declining; share count reduced by 1M shares via warrant exchange
Risk Factors
- Pre-revenue biotech with no approved products
- KRRO-121 regulatory filing and clinical trial initiation subject to regulatory approval
- Novo Nordisk collaboration remains paused
- Pre-funded warrants could still be exercised, adding 4.1M shares to the float
- Clinical-stage risk for both KRRO-121 and KRRO-111
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336685 |
| Document: krro-ex4_1.htm | 0001193125-26-336685 |
| Document: krro-ex10_1.htm | 0001193125-26-336685 |
| Document: krro-20260805.htm | 0001193125-26-336685 |
| Document: 0001193125-26-336685-index-headers.html | 0001193125-26-336685 |
| Document: 0001193125-26-336685-index.html | 0001193125-26-336685 |
| Document: 0001193125-26-336685.txt | 0001193125-26-336685 |
| 8-K Data (Synthetic) | 0001193125-26-336685 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $12.73 | awaiting T+1 | — | $13.30 (+4.48%) |
Oct 26, 2026 1d ago | Insider Buy | $12.46 | awaiting T+1 | — | $13.30 (+6.74%) |
Oct 22, 2026 5d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $13.30 (+10.37%) |
Oct 16, 2026 11d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $13.30 (+49.27%) |
Oct 5, 2026 22d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Oct 5, 2026 22d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Sep 15, 2026 6w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $13.30 (−3.83%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $13.30 (+0.08%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $13.30 (+9.74%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $13.30 (−6.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers